MedTrace Logo

A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis

NCT00259805 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-03-22

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and effectiveness of rituximab in the treatment of chronic focal encephalitis.

Conditions

  • Chronic Focal Encephalitis
  • Rasmussen's Encephalitis

Interventions

DRUG

Rituximab

375 mg/m2 given as an IV infusion once weekly for four doses

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • California Pacific Medical Center Research Institute

    lead OTHER

Principal Investigators

  • Kenneth D Laxer, M.D. · California Pacific Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259805 on ClinicalTrials.gov